All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-03-22T09:49:21.000Z

EBMT 2018 | Efficacy of allogeneic stem cell transplantation in amyloidosis patients

Mar 22, 2018
Share:

Bookmark this article

The MM Hub were delighted to attend the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation held in Lisbon, Portugal, from 18–21 March 2018. On Monday 19 March 2018 the oral abstract session 4 was held. The session was moderated by Catarina Geraldes, from the University of Coimbra, Portugal and Tamás Masszi, from Semmelweis University, Budapest, Hungary.

The third talk of this session was given by Stefan Schönland, from the University of Heidelberg, Heidelberg, Germany, who presented an abstract entitled: Improved survival after allogeneic stem cell transplantation for light chain amyloidosis: a retrospective analysis in 55 patients of the chronic malignancy working party (EBMT). This was a non-interventional clinical study (NIS) within ProMISe.

Patients characteristics:

  • N =55 pts; that underwent transplant between 1987 and 2015; 29 male pts
  • Dominant amyloid organ involvement = kidney, heart and soft-tissue
  • Median interval from first diagnosis to allo-SCT = 21 months
  • Line of therapy for allogeneic stem-cell transplantation (allo-SCT): First = 22 pts; Second = 30 pts; Third = 3 pts
  • Stem cell source: Peripheral blood (PB) = 42 pts; Bone Marrow (BM) = 12; Cord Blood (CB) = 1 pt
  • Conditioning regimen: myeloablative = 12 pts; total body irradiation (TBI) = 32 pts (mostly 2 Gy); anti-thymocyte globulin (ATG) = 11 pts; campath = 3 pts
  • HLA matching: syngeneic = 7 pts; matched relative = 34 pts; mismatched relative = 2 pts; matched unrelated = 11 pts; mismatched unrelated = 1 pt
  • Median karnofsky index = 90% (50–100)
  • Median age = 51 years (30–67)
  • Serum creatinine = 91 μmol/l (52–902)

Key Findings:

  • Median interval:
    • Between allo-SCT and neutrophils > 0.5 = 16 days (6–29)
    • Between allo-SCT and platelets > 50 = 15 days (1–76)
  • Acute graft versus host disease (aGvHD) grade 2-4: n = 11 pts; median interval = 1.1 months from allo-SCT (0.5–3.2);
  • Chronic GvHD (cGvHD): n = 17 pts; extensive in 12; median interval = 6 months (3–50)
  • Complete remission (CR) = 28 pts; median interval from allo-SCT = 6 months
  • Relapse = 17 pts; median interval = 8 months (1–155)
  • Median follow-up = 73 months (0–286)
  • Median overall survival (OS) = 44 months
    • 1-year survival = 68% (95% CI; 57–82)
    • 10-year survival = 44% (95% CI; 32–61)
  • At last follow-up:
    • No of pts alive = 25/55 (4/7 syngeneic with OS plateau at 57%)
    •  Median follow-up = 73 months (0–286)
    • CR = 16 pts
  • Median OS (pts who were given a transplant after 2006 vs pts given a transplant before 2006) = not reached vs 21 months, P = 0.006 (63% plateau beginning at 70 months)

This study presents findings from the largest cohort of AL patients treated with allo-SCT. Allo-SCT showed feasibility and efficacy in selected AL patients, with a decrease in early mortality and long term survival.  These findings confirm the beneficial use of allo-SCT with an HLA-identical donor in heavily pretreated young and fit MM patients with AL.

  1. Schönland S. et al. Improved survival after allogeneic stem cell transplantation for light chain amyloidosis: a retrospective analysis in 55 patients of the chronic malignancy working party (EBMT). #Abstract OS4-3. 44th Annual Meeting of the European Society for Blood and Marrow Transplantation, Lisbon, Portugal.

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox